The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 27, No. 3, pp. 316-320.
© 1993 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Richer, M
Right arrow Articles by Crismon, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Richer, M
Right arrow Articles by Crismon, M.

Research Articles

Pharmacotherapy of sexual offenders

M Richer and ML Crismon

OBJECTIVE: To review the definition, sociology, pathogenesis, diagnosis, medicolegal aspects, and pharmacologic treatment of sexual offenders, with emphasis on the antiandrogens, the luteinizing hormone-releasing hormone (LHRH) antagonists, and the serotonergics. DATA SOURCES: An English-language literature search using MEDLINE (1966-1991) yielded clinical trials, case reports, editorials, and review articles. STUDY SELECTION: Emphasis was placed on comparative trials and case reports discussing pedophilia, rape, and exhibitionism. DATA EXTRACTION: Data from controlled human studies were evaluated. The trials were assessed for sample size, duration of therapy, therapeutic response, and incidence of recidivism. CONCLUSIONS: The pharmacologic management of sexual offenders is controversial, and treatment is presently focused on psychotherapy and the use of antiandrogenic medications. Few well-controlled, blinded, efficacy trials with adequate sample sizes have been conducted. The populations studied are heterogeneous, and the subjects enrolled present with different sexually coercive behaviors. Consequently, the results of these studies are difficult to extrapolate to the treatment of other sexual offenders. No convincing evidence exists that pharmacologic treatment decreases the recidivism rate. Case reports describing the use of serotonergic drugs and LHRH antagonists hopefully will promote controlled clinical trials. A social consensus must be reached concerning the ethics of using these agents as a part of the treatment of sexual offenders.


This article has been cited by other articles:


Home page
 CLIN PEDIATRHome page
J. R. Hughes
Review of Medical Reports on Pedophilia
Clinical Pediatrics, October 1, 2007; 46(8): 667 - 682.
[Abstract] [PDF]

Home page
 NEJMHome page
A. Rosler and E. Witztum
Treatment of Men with Paraphilia with a Long-Acting Analogue of Gonadotropin-Releasing Hormone
N. Engl. J. Med., February 12, 1998; 338(7): 416 - 422.
[Abstract] [Full Text] [PDF]

Home page
 Sex AbuseHome page
S. M. Dwyer
Treatment Outcome Study: Seventeen Years After Sexual Offender Treatment
Sexual Abuse: A Journal of Research and Treatment, January 1, 1997; 9(2): 149 - 160.
[Abstract] [PDF]

Home page
 Sex AbuseHome page
R. A. Prentky
Arousal Reduction in Sexual Offenders: A Review of Antiandrogen Interventions
Sexual Abuse: A Journal of Research and Treatment, January 1, 1997; 9(4): 335 - 347.
[Abstract] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1993 by Harvey Whitney Books Company.